This type of drugs is especially designed to form a clone that produces antibodies that target a specific antigen in tumor cells.

The most commonly used monoclonal antibody for B-cell lymphomas is rituximab (which targets the CD20 antigen present in lymphocytes). This therapy is given intravenously and can be administered alongside the chemotherapy regimen CHOP.

Other drugs that target CD20 are: ofatumumab.